- 1、本文档共3页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
- 5、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
- 6、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们。
- 7、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
- 8、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
Israel Becomes Chinese Pharmaceutical Companies’ Destination of Innovation
Israel Becomes Chinese Pharmaceutical Companies’ Destination of InnovationWith the growing awareness of the importance of innovation in pharmacy, Chinese pharmaceutical companies aregradually moving beyond low-value generic medicines for innovative drugs made in western countries. Israel has top innovative pharmaceutical companies in the world. Today, the nation has a striking concentration of innovative people, a culture of promoting experimentation and a spirit of the thriving entrepreneurship. Given the facts that Israel has highly transparent legal system and stable investment environment, Israel has become a hotbed of pioneering technologies, profitable business opportunities, and high investment returns. At the same time, Israel has limited domestic market. Israel is willing to export its innovative pharmaceutical technology and medical equipment to the larger Chinese market. These pharmaceutical transactions are win-win situations for both nations. Following are the three recent transactions between Chinese and Israel companies in the last year.Case Study 1: China Pharma WuXi Established a Branch in IsraelOn October 30, 2014, WuXi PharmaTech, one of the world’s largest medical research companies in China, branched out geographically by opening a representative office in Tel Aviv, Israel. In addition, WuXi will collaborate with Pontifax, an Israeli venture capital firm specializing in life science, to invest in Israli companies with promising technologies, especially those that could add to WuXi’s contract research organization services.WuXi has nearly 2,000 customers using its platform to develop and test new medicines. The company’s origins are in China, where it was established in 2000, and it now has extensive operations in the US, after it acquired Minnesota-based AppTec labs in 2008. The company’s services for the biopharmaceutical and medical device industries include testing, contract research and development, as well as pharmaceutical manufacturing se
文档评论(0)